Related Experiment Video
Updated: May 15, 2026

MicroRNA-based Regulation of Picornavirus Tropism
Published on: February 6, 2017
Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites
Arun Ammayappan1, Rebecca Nace, Kah-Whye Peng
1Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Abstract:
Vesicular stomatitis virus (VSV) is potent and a highly promising agent for the treatment of cancer. However, translation of VSV oncolytic virotherapy into the clinic is being hindered by its inherent neurotoxicity. It has been demonstrated that selected picornaviral internal ribosome entry site (IRES) elements possess restricted activity in neuronal tissues. We therefore sought to determine whether the picornavirus IRES could be engineered into VSV to attenuate its neuropathogenicity. We have used IRES elements from human rhinovirus type 2 (HRV2) and foot-and-mouth disease virus (FMDV) to control the translation of the matrix gene (M), which plays a major role in VSV virulence. In vitro studies revealed slowed growth kinetics of IRES-controlled VSVs in most of the cell lines tested. However, in vivo studies explicitly demonstrated that IRES elements of HRV2 and FMDV severely attenuated the neurovirulence of VSV without perturbing its oncolytic potency.
Insights
Engineered vesicular stomatitis virus (VSV) using picornavirus IRES elements significantly reduced neurotoxicity. This modification maintained VSV
Area of Science:
- Oncolytic virotherapy
- Viral gene therapy
- Neurovirology
Background:
- Vesicular stomatitis virus (VSV) shows promise for cancer treatment.
- VSV's clinical application is limited by neurotoxicity.
- Picornaviral internal ribosome entry site (IRES) elements can restrict neuronal activity.
Purpose of the Study:
- To engineer VSV with picornavirus IRES elements to reduce neuropathogenicity.
- To assess the impact of IRES elements on VSV neurovirulence and oncolytic potency.
Main Methods:
- Incorporated IRES elements from human rhinovirus type 2 (HRV2) and foot-and-mouth disease virus (FMDV) into VSV.
- Controlled the translation of the VSV matrix (M) gene using IRES elements.
- Evaluated IRES-controlled VSV growth kinetics in vitro and neurovirulence/oncolytic potency in vivo.
Main Results:
- In vitro studies showed slower growth kinetics for IRES-controlled VSVs in most cell lines.
- In vivo studies demonstrated severe attenuation of VSV neurovirulence by HRV2 and FMDV IRES elements.
- Oncolytic potency of VSV was not perturbed by the IRES modifications.
Conclusions:
- Picornavirus IRES elements can be effectively engineered into VSV to attenuate neurotoxicity.
- This strategy offers a promising approach to enhance the safety of VSV-based oncolytic virotherapy.
- Engineered VSV maintains its efficacy against cancer while exhibiting reduced neuropathogenicity.
Related Concept Videos
Pinching-off of Coated Vesicles
Inhibitors of Viral Protein Synthesis
Receptor-mediated Endocytosis
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
Encephalitis ll: Pathophysiology
Retrovirus Life Cycles
Subviral Agents

